Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Stem cell therapy

- PMLiVE

ReNeuron aiming to take second stem cell therapy into clinic

Will test its human retinal progenitor cell for genetic eye disease RP

- PMLiVE

Biogen Idec enlists son of NFL star for MS campaign

Tyler Campbell’s own career was cut short by neurological disease

- PMLiVE

Novartis’ Gilenya fails in difficult-to-treat form of MS

Drug no better than placebo as a treatment for primary progressive multiple sclerosis

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

- PMLiVE

Merck Serono brings electronic MS device to six more countries

RebiSmart works alongside the company's MSdialog web-based software

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

National Institute for Health and Care Excellence NICE logo

NICE denies two drugs in new MS guidance

Sativex and Fampyra too costly for NHS in England

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

- PMLiVE

AbbVie-partnered Calico unveils first licensing deal

Google’s healthcare research business gains rights to drug prospects in neurodegeneration

- PMLiVE

ReNeuron appoints new CEO

Olav Hellebø joins from Clavis Pharma

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links